These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

836 related items for PubMed ID: 19053986

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM, Hindley CE.
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [Abstract] [Full Text] [Related]

  • 3. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK, Abraham NS, Scheiman JM, Laine L, First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE, Metge CJ, Leung S, Chateau DG.
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [Abstract] [Full Text] [Related]

  • 6. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H, Bombardier C, Davis P, Russell AS, Third Canadian Consensus Conference Group.
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [Abstract] [Full Text] [Related]

  • 7. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A, Ferrandez A.
    Chin J Dig Dis; 2006 Jan; 7(3):127-33. PubMed ID: 16808792
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. NSAIDs-induced gastrointestinal damage. Review.
    Arroyo M, Lanas A.
    Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
    Chen JT, Pucino F, Resman-Targoff BH.
    J Pain Palliat Care Pharmacother; 2006 Sep; 20(4):11-32. PubMed ID: 17182503
    [Abstract] [Full Text] [Related]

  • 12. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies.
    Lanas A, Hunt R.
    Ann Med; 2006 Sep; 38(6):415-28. PubMed ID: 17008305
    [Abstract] [Full Text] [Related]

  • 13. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA, Derry S, Phillips CJ, McQuay HJ.
    BMC Musculoskelet Disord; 2006 Oct 20; 7():79. PubMed ID: 17054784
    [Abstract] [Full Text] [Related]

  • 14. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C, Chan AT, Tramontano AC, Gazelle GS.
    Ann Pharmacother; 2006 Jun 20; 40(6):1052-63. PubMed ID: 16720709
    [Abstract] [Full Text] [Related]

  • 15. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
    Laine L.
    Rev Gastroenterol Disord; 2004 Jun 20; 4 Suppl 4():S33-41. PubMed ID: 15580145
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M, Chowienczyk P, Kirkham B.
    Aust Fam Physician; 2005 Nov 20; 34(11):945-8. PubMed ID: 16299629
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ, Islam K.
    J Physiol Pharmacol; 2008 Aug 20; 59 Suppl 2():117-33. PubMed ID: 18812633
    [Abstract] [Full Text] [Related]

  • 18. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
    van der Linden MW, Gaugris S, Kuipers EJ, van Herk-Sukel MP, van den Bemt BJ, Sen SS, Herings RM.
    Pharmacoepidemiol Drug Saf; 2009 Oct 20; 18(10):880-90. PubMed ID: 19593747
    [Abstract] [Full Text] [Related]

  • 19. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants.
    Tannenbaum H, Davis P, Russell AS, Atkinson MH, Maksymowych W, Huang SH, Bell M, Hawker GA, Juby A, Vanner S, Sibley J.
    CMAJ; 1996 Jul 01; 155(1):77-88. PubMed ID: 8673987
    [Abstract] [Full Text] [Related]

  • 20. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
    Chan FK.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Oct 01; 3(10):563-73. PubMed ID: 17008926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.